AbbVie Inc. (ABBV) Shareholder Equity
- 2026-06-30: Additional Paid in Capital, Common StockUSD $23.16B; Treasury Stock, ValueUSD $10.62B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-1.16B; Retained Earnings (Accumulated Deficit)USD $-17.33B.
- 2026-03-31: Additional Paid in Capital, Common StockUSD $22.96B; Treasury Stock, ValueUSD $10.61B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-1.15B; Retained Earnings (Accumulated Deficit)USD $-17.87B.
- 2025-12-31: Additional Paid in Capital, Common StockUSD $22.50B; Treasury Stock, ValueUSD $9.15B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-1.14B; Retained Earnings (Accumulated Deficit)USD $-15.49B.
- 2025-09-30: Additional Paid in Capital, Common StockUSD $22.29B; Treasury Stock, ValueUSD $9.14B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-1.57B; Retained Earnings (Accumulated Deficit)USD $-14.23B.
AbbVie Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Additional Paid in Capital, Common Stock USD | Treasury Stock, Value USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | Common Stock, Value, Outstanding USD | Treasury Stock, Common, Shares shares | Treasury Stock, Value, Acquired, Cost Method USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Treasury Stock, Shares, Acquired shares | Accumulated Other Comprehensive Income (Loss), Other than Temporary Impairment, Not Credit Loss, Net of Tax, Available-for-sale, Debt Securities USD | Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax USD | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation USD | Treasury Stock, Shares shares |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $23.16B | $10.62B | $-1.16B | $-17.33B | $-5.93B | $-5.89B | $18.00M | 77.11M | 3 month · $9.00M 6 month · $1.50B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $22.96B | $10.61B | $-1.15B | $-17.87B | $-6.66B | $-6.61B | $18.00M | 77.08M | 3 month · $1.49B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $22.50B | $9.15B | $-1.14B | $-15.49B | $-3.27B | $-3.23B | $18.00M | 70.80M | 12 month · $980.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $22.29B | $9.14B | $-1.57B | $-14.23B | $-2.64B | $-2.60B | $18.00M | 70.79M | 3 month · $4.00M 9 month · $977.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $21.99B | $9.15B | $-1.54B | $-11.50B | $-183.00M | $-138.00M | $18.00M | 70.83M | 3 month · $10.00M 6 month · $973.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $21.81B | $9.14B | $-1.74B | $-9.53B | $1.42B | $1.46B | $18.00M | 70.78M | 3 month · $963.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $21.33B | $8.20B | $-1.93B | $-7.90B | $3.33B | $3.36B | $18.00M | 66.34M | 12 month · $1.70B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $21.16B | $7.85B | $-2.33B | $-4.96B | $6.03B | $6.07B | $18.00M | 64.31M | 3 month · $17.00M 9 month · $1.35B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $20.88B | $7.84B | $-2.51B | $-3.77B | $6.78B | $6.82B | $18.00M | 64.28M | 3 month · $9.00M 6 month · $1.33B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $20.66B | $7.83B | $-2.45B | $-2.38B | $8.01B | $8.05B | $18.00M | 64.23M | 3 month · $1.32B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $20.18B | $6.53B | $-2.31B | $-1.00B | $10.36B | $10.40B | $18.00M | 57.11M | 12 month · $1.98B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $20.02B | $6.53B | $-2.35B | $933.00M | $12.09B | $12.13B | $18.00M | 57.09M | 3 month · $4.00M 9 month · $1.97B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $19.84B | $6.53B | $-2.25B | $1.79B | $12.87B | $12.90B | $18.00M | 57.13M | 3 month · $10.00M 6 month · $1.97B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $19.62B | $6.52B | $-2.23B | $2.39B | $13.27B | $13.30B | $18.00M | 57.11M | 3 month · $1.96B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $19.25B | $4.59B | $-2.20B | $4.78B | $17.25B | $17.29B | $18.00M | 44.59M | 12 month · $1.49B | (m) | (m) | (m) | (m) | (m) | 44.59M |
| 2022-09-30 | $19.06B | $4.59B | $-3.44B | $4.95B | $15.99B | $16.03B | $18.00M | (m) | 3 month · $4.00M 9 month · $1.48B | (m) | (m) | (m) | (m) | (m) | 44.57M |
| 2022-06-30 | $18.91B | $4.59B | $-3.20B | $3.52B | $14.65B | $14.69B | $18.00M | (m) | 3 month · $9.00M 6 month · $1.48B | (m) | (m) | (m) | (m) | (m) | 44.60M |
| 2022-03-31 | $18.73B | $4.58B | $-2.98B | $5.10B | $16.28B | $16.31B | $18.00M | (m) | 3 month · $1.47B | (m) | (m) | (m) | (m) | (m) | 44.56M |
| 2021-12-31 | $18.30B | $3.14B | $-2.90B | $3.13B | $15.41B | $15.44B | $18.00M | (m) | 12 month · $934.00M | (m) | (m) | (m) | (m) | (m) | 34.86M |
| 2021-09-30 | $18.11B | $3.02B | $-3.16B | $1.60B | $13.55B | $13.58B | $18.00M | (m) | 3 month · $6.00M 9 month · $803.00M | (m) | (m) | (m) | (m) | (m) | 33.97M |
| 2021-06-30 | $17.94B | $3.02B | $-3.10B | $740.00M | $12.57B | $12.59B | $18.00M | (m) | 3 month · $10.00M 6 month · $797.00M | (m) | (m) | (m) | (m) | (m) | 34.02M |
| 2021-03-31 | $17.71B | $3.02B | $-3.29B | $2.29B | $13.71B | $13.73B | $18.00M | (m) | 3 month · $787.00M | (m) | (m) | (m) | (m) | (m) | 33.97M |
| 2020-12-31 | $17.38B | $2.26B | $-3.12B | $1.05B | $13.08B | $13.10B | $18.00M | (m) | 12 month · $978.00M | (m) | (m) | (m) | (m) | (m) | 27.01M |
| 2020-09-30 | $17.15B | $1.97B | $-3.26B | $3.33B | $15.27B | $15.29B | $18.00M | (m) | 3 month · $20.00M 9 month · $682.00M | (m) | (m) | (m) | (m) | (m) | 24.25M |
| 2020-06-30 | $16.95B | $1.96B | $-3.44B | $3.13B | $14.71B | $14.73B | $18.00M | (m) | 3 month · $19.00M 6 month · $662.00M | (m) | (m) | (m) | (m) | (m) | 24.14M |
| 2020-03-31 | $15.40B | $25.11B | $-3.70B | $5.97B | $-7.42B | $-7.42B | $18.00M | (m) | 3 month · $643.00M | (m) | (m) | (m) | (m) | (m) | 309.57M |
| 2019-12-31 | $15.19B | $24.50B | $-3.60B | $4.72B | $-8.17B | $-8.17B | $18.00M | (m) | 12 month · $428.00M | (m) | (m) | $0.00 | (m) | (m) | 302.67M |
| 2019-09-30 | $15.11B | $24.50B | $-2.53B | $3.67B | $-8.23B | $-8.23B | $18.00M | (m) | 3 month · $3.00M 9 month · $425.00M | (m) | (m) | $0.00 | (m) | (m) | 302.65M |
| 2019-06-30 | $15.03B | $24.50B | $-2.49B | $3.38B | $-8.57B | $-8.57B | $18.00M | (m) | 3 month · $3.00M 6 month · $422.00M | (m) | (m) | $0.00 | (m) | (m) | 302.69M |
| 2019-03-31 | $14.94B | $24.50B | $-2.52B | $4.23B | $-7.83B | $-7.83B | $18.00M | (m) | 3 month · $419.00M | (m) | (m) | $0.00 | (m) | (m) | 302.65M |
| 2018-12-31 | $14.76B | $24.11B | $-2.48B | $3.37B | $-8.45B | $-8.45B | $18.00M | (m) | 12 month · $12.21B | (m) | (m) | $0.00 | (m) | (m) | 297.69M |
| 2018-09-30 | $14.68B | $21.85B | $-2.56B | $6.79B | $-2.92B | (m) | $18.00M | (m) | 3 month · $1.01B 9 month · $9.96B | (m) | (m) | $0.00 | (m) | (m) | 271.95M |
| 2018-06-30 | $14.60B | $20.84B | $-2.64B | $5.50B | $-3.38B | (m) | $18.00M | (m) | 3 month · $7.52B 6 month · $8.95B | (m) | (m) | $0.00 | (m) | (m) | 261.56M |
| 2018-03-31 | $14.52B | $13.33B | $-2.63B | $4.98B | $3.55B | (m) | $18.00M | (m) | 3 month · $1.43B | (m) | (m) | $0.00 | (m) | (m) | 188.74M |
| 2017-12-31 | $14.27B | $11.92B | $-2.73B | $5.46B | $5.10B | $5.10B | $18.00M | (m) | 12 month · $1.12B | (m) | 12 month · 13.00M | $0.00 | (m) | (m) | 176.61M |
| 2017-09-30 | $14.15B | $11.42B | $-2.61B | $6.55B | $6.69B | (m) | $18.00M | (m) | (m) | (m) | 9 month · 7.80M | (m) | (m) | (m) | 171.30M |
| 2017-06-30 | $14.02B | $11.43B | $-2.55B | $5.95B | $6.01B | (m) | $18.00M | (m) | (m) | (m) | 6 month · 7.80M | (m) | (m) | (m) | 171.42M |
| 2017-03-31 | $13.89B | $11.43B | $-2.54B | $5.06B | $5.00B | (m) | $18.00M | (m) | (m) | (m) | 3 month · 7.80M | (m) | (m) | (m) | 171.46M |
| 2016-12-31 | $13.68B | $10.85B | $-2.59B | $4.38B | $4.64B | (m) | $18.00M | (m) | 12 month · $6.02B | (m) | 12 month · 34.00M | $0.00 | (m) | (m) | 162.39M |
| 2016-09-30 | $13.54B | $8.76B | $-2.34B | $4.01B | $6.47B | (m) | $18.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 138.08M |
| 2016-06-30 | $13.05B | $8.38B | $-2.39B | $3.35B | $5.64B | (m) | $18.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 132.71M |
| 2016-03-31 | $13.29B | $8.92B | $-2.42B | $2.67B | $4.64B | (m) | $18.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 140.65M |
| 2015-12-31 | $13.08B | $8.84B | $-2.56B | $2.25B | $3.94B | (m) | $17.00M | (m) | 12 month · $7.89B | (m) | 12 month · 46.00M | (m) | (m) | (m) | 139.13M |
| 2015-09-30 | $13.01B | $7.31B | $-2.50B | $1.65B | $4.86B | (m) | $17.00M | (m) | (m) | (m) | 9 month · 21.00M | (m) | (m) | (m) | 113.60M |
| 2015-06-30 | $12.42B | $5.82B | $-2.37B | $1.26B | $5.50B | (m) | $17.00M | (m) | (m) | (m) | 6 month · 4.00M | (m) | 6 month · $33.00M | (m) | 92.14M |
| 2015-03-31 | $4.40B | $1.31B | $-2.47B | $739.00M | $1.38B | (m) | $16.00M | (m) | (m) | (m) | 3 month · 4.00M | (m) | 3 month · $5.00M | (m) | 23.99M |
| 2014-12-31 | $4.19B | $972.00M | $-2.03B | $535.00M | $1.74B | (m) | $16.00M | (m) | 12 month · $665.00M | (m) | 12 month · 9.00M | (m) | 12 month · $-123.00M | (m) | 18.13M |
| 2014-09-30 | $4.08B | $672.00M | $-913.00M | $2.13B | $4.64B | (m) | $16.00M | (m) | (m) | (m) | 9 month · 5.00M | (m) | 9 month · $-102.00M | (m) | 13.63M |
| 2014-06-30 | $4.00B | $673.00M | $-420.00M | $2.30B | $5.22B | (m) | $16.00M | (m) | (m) | (m) | 6 month · 5.00M | (m) | 6 month · $-59.00M | (m) | 13.66M |
| 2014-03-31 | $3.90B | $672.00M | $-426.00M | $1.87B | $4.70B | (m) | $16.00M | (m) | (m) | (m) | 3 month · 5.00M | (m) | 3 month · $-24.00M | (m) | 13.59M |
| 2013-12-31 | $3.67B | $320.00M | $-442.00M | $1.57B | $4.49B | (m) | $16.00M | (m) | 12 month · $223.00M | (m) | 12 month · 4.00M | (m) | 12 month · $-79.00M | 12 month · $-38.00M | 6.90M |
| 2013-09-30 | $3.58B | $119.00M | $-981.00M | $1.08B | $3.58B | (m) | $16.00M | (m) | (m) | (m) | 9 month · 500.00K | (m) | 9 month · $-61.00M | (m) | 3.10M |
| 2013-06-30 | $4.07B | $121.00M | $-1.17B | $758.00M | $3.56B | (m) | $16.00M | (m) | (m) | (m) | 6 month · 500.00K | (m) | (m) | (m) | 3.13M |
| 2013-03-31 | $3.94B | $97.00M | $-1.24B | $330.00M | $2.96B | (m) | $16.00M | (m) | (m) | 3 month · $87.00M | 3 month · 0.00 | (m) | (m) | (m) | 2.57M |
| 2012-12-31 | (m) | (m) | $-350.00M | (m) | $-350.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $11.00M | (m) | (m) |
| 2011-12-31 | (m) | (m) | $-25.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $13.00M | (m) | (m) |
| 2010-12-31 | (m) | (m) | $288.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |